StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) stock

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.28+0.02 (+1.59%)

Close on Nov 20, 2026Market cap $2.35MP/E –Yield –

NeuroSense Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2025 it was -$11.13M. The highest annual figure on record is -$3.22M in fiscal 2021.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.13M–
FY2024Dec 31, 2024-$10.21M–
FY2023Dec 31, 2023-$10.11M–
FY2022Dec 31, 2022-$10.49M–
FY2021Dec 31, 2021-$3.22M–

More NeuroSense Therapeutics figures

See a number that looks wrong?